Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envometinib
- Development stage
- Unknown
- Lead developer
- Immuneering
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Envometinib (IMM-6-415) is an orally bioavailable, small molecule "Deep Cyclic Inhibitor" of MEK, developed by Immuneering. It is designed to provide deep and durable inhibition of the RAS/RAF/MAPK pathway while utilizing a cyclic dosing schedule to improve the therapeutic window and minimize toxicities associated with continuous MEK inhibition. The drug is primarily being developed for the treatment of advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations. As of mid-2024, it has completed Phase 1 clinical trials and is considered Phase 2-ready.
- Other names
- envometinibIMM-6-415IMM6-415IMM 6-415
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on envometinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envometinib.